Autoantibody profile stratified by anti-cN-1A antibody status
| Antibody | Anti-cN-1A positive (%) | Anti-cN-1A negative (%) | OR (95% CI) | p Value |
|---|---|---|---|---|
| Antinuclear antibodies (n=132) | 1/47 (2.1) | 1/85 (1.2) | 1.83 (0.11 to 29.88) | 0.673 |
| Anti-DNA antibodies (n=119) | 3/42 (7.1) | 1/77 (1.3) | 5.85 (0.59 to 58.07) | 0.132 |
| Anti-Sm antibodies (n=97) | 0/33 (0.0) | 1/64 (1.6) | 1 | – |
| Antineutrophil cytoplasmic antibodies (n=96) | 0/32 (0.0) | 0/64 (0.0) | – | – |
| Antimitochondrial antibodies (n=128) | 0/41 (0.0) | 0/87 (0.0) | – | – |
| Antiextractable nuclear antigens antibodies (n=102) | 4/34 (11.8) | 5/68 (7.4) | 1.68 (0.42 to 6.71) | 0.463 |
| Anti-SSA (Ro) (n=228) | 19/76 (25.0) | 22/152 (14.5) | 1.97 (0.99 to 3.92) | 0.054 |
| Anti-SSB (La) (n=228) | 13/76 (17.1) | 9/152 (5.9) | 3.28 (1.33 to 8.07) | 0.010* |
| (U1)RNP antibodies (n=223) | 1/74 (1.4) | 0/149 (0.0) | 1 | – |
| Antitopoisomerase I (Scl70) (n=222) | 0/72 (0.0) | 0/150 (0.0) | – | – |
| Anti-Jo1 (n=228) | 1/76 (1.3) | 0/152 (0.0) | 1 | – |
| Other myositis-specific antibody (OMSA)† (n=193) | 0/60 (0.0) | 1/133 (0.8) | 1 | – |
| Other myositis-associated antibody (OMAA) (n=128) | 0/41 (0.0) | 0/87 (0.0) | – | – |
Figures in brackets represent within antibody group percentages. n represents data available for analysis per variable (of a total of 311). p Value is derived from logistic regression.
*Adjusted (for anti-SSA antibodies, presence of autoimmune disorders, age at disease onset, gender and comorbidities) OR 2.11, 95% CI 0.52 to 8.67, p=0.297.
†One patient found positive for anti-SRP antibodies. In this case, no relevant clinical correlation was identified, and the relevance of this finding is uncertain.
Anti-cN-1A, anticytosolic 5′-nucleotidase 1A; OMAA, anti-Ku, anti-RNA polymerase I/II/III, anti-PM/SCL, anti-NOR90; OMSA, anti-TIF1 complex, anti-SAE, anti-NXP2, anti-MDA5, anti-SRP, anti-Mi-2, anti-PL12, anti-PL7, anti-EJ, anti-KS, anti-OJ, anti-Zo.